Table 2.

Newer recipient-oriented therapies for AKI.

Injury and Inflammation in Mediating AKI
Thymoglobulin/CNI-sparing regimens—“PREDICT” trial, NCT02056938 (https://www.clinicaltrials.gov/ct2/show/NCT02056938, accessed on 1 February 2021)
Inhaled carbon monoxide
Recombinant P and E selectin ligand
Anti-intracellular adhesion molecule 1 antibody
Complement inhibitors
C1-esterase inhibitor
Anti-C5 antibody—eculizumab, “PROTECT” trial, NCT02145182 (https://clinicaltrials.gov/ct2/show/NCT02145182, accessed on 1 February 2021)
Cell death and protective factors in mediating AKI and recovery
Hepatocyte growth factor—NCT02474667, and refanalin IV (https://clinicaltrials.gov/ct2/show/NCT02474667, accessed on 1 February 2021)
Diannexin—NCT01442337 (https://clinicaltrials.gov/ct2/show/NCT01442337, accessed on 1 February 2021)
siRNA-targeting p53 (QP-1002)—“ReGIFT” trial; NCT02610296 (https://clinicaltrials.gov/ct2/show/NCT02610296, accessed on 1 February 2021)

AKI, acute kidney injury; CNI, calcineurin-inhibitors; C1, complement 1 (Mannon et al. [22]).